Check for updates

Exploration

RESEARCH ARTICLE OPEN ACCESS

Targeting MGAT4A-Mediated N-Glycosylation as a Therapeutic Strategy to Inhibit Glioblastoma Stem Cell Invasion

Rui Niu[1] | Meichen Liu[1,2,3] | Qingshan Yang[1] | Jinlong Yin[1]

[1]Henan Key Laboratory of Brain Targeted Bio-nanomedicine, School of Life Sciences, Henan University, Kaifeng, Henan, China | [2]School of Basic Medical Science, Henan University, Kaifeng, Henan, China | [3]Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Republic of Korea, Goyang

Correspondence: Jinlong Yin (jlyin@henu.edu.cn)

Received: 9 April 2025 | **Revised:** 23 October 2025 | **Accepted:** 17 November 2025

Keywords: EGFR | glioblastoma stem cell | invasion | MGAT4A | nanocapsule

ABSTRACT

Glioblastoma (GBM) is the most aggressive type of primary brain tumor, and its invasive properties contribute significantly to incomplete surgical resection and tumor recurrence. Despite extensive clinical efforts to mitigate GBM invasion, targeted therapies against GBM stem cells (GSCs), which drive invasion, remain incompletely understood. Here, we report that MGAT4A, a key glycosyltransferase involved in N-glycosylation, orchestrates EGFR-ERK1/2 signaling to promote GSC invasion. Elevated MGAT4A expression correlates with poor survival outcomes in GBM patients, highlighting its potential as a therapeutic target. Silencing MGAT4A inhibits GSC invasion and tumorigenic capacities, including self-renewal and proliferation, both in vitro and in an orthotopic brain tumor xenograft model. Proteomic N-glycosylation mapping and co-immunoprecipitation assays reveal that MGAT4A interacts with EGFR and catalyzes N-glycosylation at the EGFR N604 site. This modification triggers ERK1/2 phosphorylation, thereby driving the invasion and tumorigenic potential of GSCs. Notably, tunicamycin, an N-glycosylation inhibitor, significantly impedes GSC invasion and disrupts downstream EGFR-ERK1/2 signaling, extending survival in mice bearing orthotopic tumors. To specifically target MGAT4A, we developed a CRISPR-Cas9 sgRNA-based nanotechnology, which notably reduced GSC invasion and improved survival in mice. Collectively, our study elucidates a novel mechanistic pathway driving GSC invasion and positions MGAT4A as a promising therapeutic target for GBM.

1 | Introduction

Glioblastoma (GBM) is a rapidly growing and aggressive tumor, representing the most common and deadly primary malignant brain cancer, and one of the most challenging malignancies in oncology [1]. Despite progress in therapeutic approaches, clinical outcomes remain poor, with a median patient survival of just 15 months [2–4]. Treatment failure is largely attributed to the tumor's diffuse infiltration into surrounding brain tissue, resulting in inevitable recurrence, and its intrinsic resistance to conventional therapies [5–8]. Another factor contributing to treatment failure is the presence of glioblastoma stem cells (GSCs) [9, 10]. According to the cancer stem cell (CSC) theory, GSCs drive resistance to chemotherapy and radiotherapy, and play key roles in tumor invasion and metastasis [10–15]. Therefore, understanding the mechanisms that regulate GSC invasion is crucial for developing effective therapeutic strategies.

Glycosylation is a vital post-translational modification of glycoproteins, producing structurally diverse glycans that are essential

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2026 The Author(s). *Exploration* published by Henan University and John Wiley & Sons Australia, Ltd.

for the precise regulation of numerous biological processes [16–18]. The biosynthesis of glycoproteins and glycan chains is carried out through the coordinated and sequential action of glycosyltransferases and glycosidases, primarily in the endoplasmic reticulum (ER) and Golgi apparatus (GA). Disruptions in glycosylation can result in a wide range of cellular and systemic dysfunctions, affecting specific cell types and tissues [19–21]. Aberrant glycosylation in cancer was first reported over 50 years ago [22], and growing evidence since then has underscored its significant role in tumor development. Glycans are now recognized as key regulators of cancer cell proliferation, invasion, metastasis, and angiogenesis [23–28]. Glycosylation modifications of proteins, regulated by glycosyltransferases, include both N-glycosylation and O-glycosylation [29, 30]. As one of the most common post-translational modifications, N-glycosylation is essential for the proper folding, stability, and function of many secreted and cell surface proteins [31–33]. N-acetylglucosaminyltransferases (GnTs) are responsible for synthesizing the branching structures of complex N-glycans in the Golgi apparatus [34]. These enzymes are classified into various isoforms depending on their functions, including GnT-I, GnT-II, GnT-III, GnT-IV, GnT-V, GnT-VI, and GnT-IX. They are primarily responsible for catalyzing the transfer of N-acetylglucosamine (GlcNAc) to the core pentasaccharide of N-glycans, thereby forming different branches in the glycoprotein N-glycan chain [34–37]. Previous studies have shown that certain glycosyltransferases, such as GnT-IV, GnT-V, and GnT-IX, promote tumor invasion and metastasis by initiating the extension of poly-N-acetyllactosamine branching structures. In contrast, GnT-III inhibits tumor metastasis by catalyzing the formation of bisected glycoconjugate structures, preventing the formation of other branching structures and thus impeding the action of other glycosyltransferases [37, 38]. Therefore, inhibiting abnormal glycosylation or targeting glycans could provide a novel therapeutic approach for glioma treatment [39, 40].

MGAT4A (Mannosyl (alpha-1, 3)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A) encodes the GnT-IVA glycosyltransferase, a member of the N-acetylglucosaminyltransferase family. Its primary function is to catalyze the attachment of N-acetylglucosamine to the α-1,3-linked mannose (Man) in the N-glycan core through a β-1,4 glycosidic bond, thereby producing tri- and tetra-antennary structures of complex N-glycans [41, 42]. MGAT4A is one of two isozymes of GnT-IV (MGAT4A and MGAT4B) [43, 44]. Although both share substrate specificity, MGAT4A displays higher enzymatic activity and substrate affinity, making it the predominant isozyme involved in the synthesis of β-1,4-branched N-glycans [44, 45]. Therefore, it is widely accepted that the synthesis of β-1, 4 branching structures in complex N-glycan chains on glycoproteins is primarily catalyzed by MGAT4A [43, 45]. Abnormal expression of MGAT4A has been observed in various tumor cells, including choriocarcinoma [46–48], hepatocarcinoma [49, 50], colorectal carcinoma [51], and pancreatic cancer [52]. These studies suggest a close association between MGAT4A expression and tumor cell invasion and migration. Despite these findings, the biological significance of MGAT4A in GSC invasion remains unclear, and the molecular mechanisms underlying its regulatory role are yet to be fully explored.

In this study, we demonstrate that MGAT4A plays a pivotal role in promoting GSC invasion and tumorigenesis. MGAT4A catalyzes the N-glycosylation of EGFR at the N604 site, enhancing EGFR-ERK1/2 signaling, which in turn facilitates GSC invasion and tumorigenesis. We further show that silencing MGAT4A through lentivirus-mediated knockdown and inhibiting N-glycosylation with tunicamycin both significantly reduce GSC invasion and tumorigenicity in vitro and in an orthotopic xenograft model. Additionally, we develop a novel CRISPR-Cas9 sgRNA-based nanotechnology to specifically target MGAT4A, which effectively suppresses EGFR-ERK1/2 signaling and tumorigenesis in the orthotopic xenograft model. These findings highlight the essential role of MGAT4A in GSC-driven GBM and propose a novel therapeutic avenue for treating diffuse GBM.

2 | Results

2.1 | MGAT4A Expression Associated With GSC Invasion and Poor Prognosis in GBM Patients

To identify potential regulators of invasion in GBM progression, we conducted a retrospective analysis of our previously published RNA-seq data comparing invasive and non-invasive GSCs [15]. Since abnormal surface glycosylation has been identified as a characteristic of cancer [21, 25, 26], we focused on genes involved in protein glycosylation. Our analysis revealed that MGAT4A, among the top 10 differentially expressed genes (including IGFBP5, TXLNB, RGS16, HOXD3, EMILIN1, FREM2, ARC, HOXD4, SIPA1L2, and MGAT4A), was the only gene associated with glycosylation pathways (Table S1). MGAT4A is an N-acetylglucosaminyltransferase primarily involved in protein glycosylation by synthesizing the branching structures of intricate N-glycans in the Golgi complex. Its irregular activity has been linked to a range of cancers, such as choriocarcinoma [47, 48], pancreatic cancer [52], and hepatocarcinoma [41, 49], where it is often seen as a factor in the spread and movement of cancer cells. Yet, the precise function and the processes behind MGAT4A's involvement in GSC invasion are still not clear. Thus, we selected MGAT4A as a candidate for further investigation.

To assess the clinical significance of MGAT4A in GBM, an in silico study was conducted with glioma data sources accessible to the public. Elevated mRNA expression of MGAT4A was observed in GBM samples compared to normal tissues in both the Gravendeel and The Cancer Genome Atlas (TCGA) datasets (Figure 1A,B). Survival analysis indicated that high MGAT4A expression was strongly associated with poor prognosis in glioma patients in both the Gravendeel dataset ($p = 0.0017$) and the TCGA dataset ($p = 0.0032$) (Figure 1C,D). Next, we analyzed the expression level of MGAT4A with normal astrocytes (HA1800) and GSCs (X01, 448, GSC924, 83, and 131) using RT-qPCR (Figure 1E) and immunoblot (IB) analysis (Figure S1A). The results revealed differential expression of MGAT4A between invasive (X01, 448, GSC924) and non-invasive (83, 131) GSCs, with MGAT4A being highly expressed in the invasive GSCs.

To investigate whether MGAT4A regulates GSC invasion, we suppressed MGAT4A in invasive GSCs (X01, 448, and GSC924) with two distinct shRNAs and performed in vitro invasion

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 1 | MGAT4A expression is associated with GSC invasion and poor prognosis in GBM patients. (A) MGAT4A mRNA expression in normal and GBM by the Gravendeel dataset. (B) MGAT4A mRNA expression in normal and GBM by the TCGA dataset. (C) Kaplan–Meier survival curves for all glioma patients with high or low MGAT4A expression based on the median expression in the Gravendeel dataset. (D) Kaplan–Meier survival curves for all glioma patients with high or low MGAT4A expression based on the median expression in the TCGA dataset. (E) RT-qPCR validation of MGAT4A expression in GSCs. Data are represented as mean ± SEM ($n = 3$). (F–N) Immunoblot (IB) analysis of MGAT4A expression in X01 (F), 448 (I), and GSC924 (L) GSCs infected with shCtrl, shMGAT4A-1, or shMGAT4A-2 lentivirus. GAPDH was used as a loading control; RT-qPCR analysis of MGAT4A mRNA expression in X01 (G), 448 (J), and GSC924 (M) GSCs infected with shCtrl, shMGAT4A-1, or shMGAT4A-2 lentivirus. Data are presented as mean ± SEM ($n = 3$). Invasion assays with X01 (H), 448 (K), and GSC924 (N) GSCs infected with shCtrl, shMGAT4A-1, or shMGAT4A-2 lentivirus. Images taken after 48 h of invasion are representative of three independent experiments (scale bar, 50 μm), and (right) the graph shows the mean number of invasive cells ± SEM ($n = 3$). (O) Luminescence images of the whole brains of mice bearing orthotopic xenografts of X01-luc GSCs infected with shCtrl, shMGAT4A-1, and shMGAT4A-2 lentivirus. (P) Body weight changes in mice following injection X01-luc GSCs infected with shCtrl, shMGAT4A-1, and shMGAT4A-2 lentivirus. Data are presented as mean ± SEM ($n = 6$, one-way ANOVA and Tukey multiple comparisons tests). (Q) Kaplan–Meier survival curves of mice implanted with X01-luc GSCs infected with shCtrl, shMGAT4A-1, or shMGAT4A-2 lentivirus ($n = 6$, 5×10^4 cells/mouse). Significant results are presented as $^{**}p < 0.01$, $^{***}p < 0.001$, $^{****}p < 0.0001$, by two-tailed Student's *t*-test, one-way ANOVA analysis, or log-rank test.

assays (Figure 1F–N). Successful knockdown of MGAT4A was confirmed by IB (Figure 1F,I,L) and RT-qPCR (Figure 1G,J,M). Additionally, invasion assays demonstrated that shMGAT4A notably reduced the invasion of GSCs compared to shCtrl (Figure 1H,K,N). To investigate the function of MGAT4A in GSC invasion and tumorigenicity in vivo, we established xenograft mouse models. These models used X01-luc GSC, which had been stably expressing luciferase, and were subsequently infected with shMGAT4A or shCtrl lentiviral. Inhibition of MGAT4A in X01-luc GSC significantly decreased intracranial tumor volume (Figure 1O). The body weight of mice showed minimal changes compared to the shCtrl group (Figure 1P), and MGAT4A knockdown notably prolonged mice survival (Figure 1Q). In addition, H&E staining analysis revealed distinct invasive behaviors between the experimental groups. The shCtrl control group exhibited robust invasive properties, with GSCs infiltrating the injected hemisphere and extensively migrating through the corpus callosum into the contralateral hemisphere (red box, Figure S1B). In striking contrast, shMGAT4A group markedly diminished invasive capacity (green box, Figure S1B). These findings emphasize that MGAT4A knockdown suppressed both the invasion and tumorigenic potential of invasive GSCs, both in vitro and in vivo.

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

2.2 | MGAT4A Regulates the Proliferation and Self-Renewal of GSCs

To evaluate the function of MGAT4A in GSC maintenance, we assessed the impact of MGAT4A knockdown on GSC proliferation and self-renewal capacity (Figure S1C–H). Knockdown of MGAT4A inhibited cell growth (Figure S1C,E,G) and significantly reduced tumorsphere formation frequency in X01, 448, and GSC924 GSCs, as assessed by the in vitro limiting dilution assay (Figure S1D,F,H).

To assess whether increased MGAT4A expression exerts similar effects, we regulated MGAT4A expression in 83 and 131 GSCs through ectopic overexpression (Figure S2A–J). IB and RT-qPCR analysis confirmed successful overexpression of MGAT4A (Figure S2A,B,D,E). As expected, invasion assays demonstrated that MGAT4A overexpression notably enhanced the invasiveness in 83 and 131 GSCs (Figure S2C,F). Similarly, ectopic overexpression of MGAT4A notably promoted the growth and self-renewal capacity of 83 and 131 non-invasive GSCs (Figure S2G–J). These findings strongly imply that MGAT4A regulates the invasion, proliferation, and self-renewal capacity of GSCs.

2.3 | MGAT4A Modulates Protein N-Glycosylation in GSCs

MGAT4A is an N-acetylglucosamine transferase that plays a role in the synthesis of N-glycans on protein surfaces. It transfers N-acetylglucosamine to the α-1,3-mannose arm, thereby catalyzing the formation of β-1,4 glycosidic bonds. To systematically evaluate the regulatory role of MGAT4A in protein N-glycosylation, we performed changes in protein N-glycosylation levels in X01 and 448 GSCs with MGAT4A knockdown, and in 83 and 131 GSCs with ectopic overexpression of MGAT4A, using lectin blot analysis (Figure 2A,B). Our results showed that knockdown of MGAT4A in X01 and 448 GSCs significantly decreased protein N-glycosylation levels, whereas ectopic overexpression of MGAT4A in 83 and 131 GSCs significantly increased protein N-glycosylation levels. These findings suggest that MGAT4A regulates protein N-glycosylation in GSCs.

To further explore the molecular mechanisms by which MGAT4A affects protein N-glycosylation and to identify the potential signaling pathways involved, we performed mass spectrometry-based protein N-glycosylation sequencing in 83 GSC infected with either MGAT4A-overexpressing or vector-control lentivirus. The majority of the peptides that were identified had lengths ranging from 7 to 20 amino acid residues, aligning with the anticipated range derived from trypsin's enzymatic chopping and HCD's fragmentation process. This result meets the quality control standards (Figure 2C). In the mass spectrometry analysis, most of the identified proteins had either one N-glycosylation site (53.96%) or two N-glycosylation sites (26.37%) (Figure 2D, top). Gene ontology (GO) cellular component enrichment analysis revealed that 41.78% and 39.76% of the proteins with N-glycosylation modifications were localized to the extracellular region and plasma membrane, respectively (Figure 2D, bottom). Differential analysis of modification sites revealed that, compared with the vector-control group, 119 N-glycosylation sites of 100 proteins were upregulated after overexpression of MGAT4A (fold change ≥ 1.5; $p < 0.05$), while 65 N-glycosylation sites of 54 proteins were downregulated (fold change $\leq 1/1.5$; $p < 0.05$) (Figure 2E). Further examination of the N-glycosylation sites of these differentially expressed proteins, which were upregulated more than 10 times, identified several significantly differentially expressed protein N-glycosylation sites, including intercellular adhesion molecule 1 (ICAM1, N267), cation-dependent mannose-6-phosphate receptor (M6PR, N107, N113), epidermal growth factor receptor (EGFR, N603, N604), alpha-N-acetylgalactosaminidase (NAGA, N201), alpha-glucosidase (GAA, N925) (Figure 2F). Gene ontology (GO) enrichment analysis indicated that the upregulated proteins were primarily enriched in biological processes associated with the regulation of apoptotic processes and programmed cell death (Figure 2G), suggesting that MGAT4A may be closely associated with cell apoptosis.

2.4 | Knockdown of MGAT4A Induces GSC Apoptosis by Inhibiting EGFR-ERK1/2 Signaling

Next, we further verify the analysis results of the above glycosylation sequencing. We found that among the top 3 glycosylated proteins, the changes in ICAM1 and M6PR were not correlated with the expression of MGAT4A, while the changing trend of EGFR was consistent (Figure S3A,B). Additionally, lectin blot analysis following co-IP in X01 GSC clearly showed that knockdown of MGAT4A significantly reduced the L-PHA level of EGFR (Figure S3C). Notably, EGFR exhibited a positive correlation with MGAT4A in the CGGA database (Figure S3D). Based on these observations, we speculate that EGFR might be crucial in regulating protein N-glycosylation and cell apoptosis mediated by MGAT4A. EGFR, which binds to the EGF, is pivotal in cellular growth and the transmission of signals [53]. The cell communicates with its nucleus by sending out signals that promote cell proliferation and prevent cell death. This communication occurs via a host of signaling pathways, such as PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and JAK/STAT [54, 55]. In this way, it plays a key role in managing how cells grow and replicate. To investigate how MGAT4A influences the EGFR pathway, we assessed the classical downstream signaling events of EGFR. Our results revealed that knockdown of MGAT4A in X01 GSC decreased EGFR levels, and a corresponding reduction in p-ERK1/2 levels (Figure 2H). Conversely, overexpression of MGAT4A in 83 GSC resulted in increased EGFR expression and elevated p-ERK1/2 levels (Figure 2I). However, unlike p-ERK1/2, p-AKT, and p-STAT3 did not show consistent changes (Figure 2H,I), suggesting that MGAT4A modulates the growth and apoptosis of GSCs by regulating the EGFR-ERK1/2 signaling pathway.

GO analysis indicated that MGAT4A is closely associated with apoptosis. To further investigate this relationship, we assessed the presence of apoptosis-related proteins and apoptosis occurrences within GSCs. We performed IB analysis to examine the presence of apoptosis-related proteins in X01, 448, and GSC924 GSCs infected with either shCtrl, shMGAT4A-1, or shMGAT4A-2 lentivirus. Knockdown of MGAT4A resulted in increased levels of apoptosis-related proteins, specifically cleaved-Caspase3 and cleaved-PARP (Figure 3A). Flow cytometry analysis further corroborated that apoptosis was significantly promoted by knockdown MGAT4A in X01 and 448 GSCs (Figure 3B).

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 2 | MGAT4A modulates protein N-glycosylation in GSCs. (A) Lectin blot analysis of protein N-glycosylation in X01 and 448 GSCs infected with shCtrl, shMGAT4A-1, or shMGAT4A-2 lentivirus. GAPDH was used as a loading control. (B) Lectin blot analysis of protein N-glycosylation in 83 and 131 GSCs infected with MGAT4A or vector control lentivirus. GAPDH was used as a loading control. (C) Distribution of peptide segment lengths identified by mass spectrometry. (D) The number and subcellular localization of N-glycosylation sites in proteins analyzed by mass spectrometry. (E) Sequence analysis of protein N-glycosylation mass spectrometry of exogenous overexpression MGAT4A in 83 GSC. (F) Analysis of upregulated protein and N-glycosylation sites in 83 GSC infected with MGAT4A or vector-control lentivirus based on protein N-glycosylation mass spectrometry sequencing. (G) Bubble chart showing the top 10 functional enrichment analysis with genes upregulated. (H) IB analysis of MGAT4A, EGFR, ERK1/2, p-ERK1/2, AKT, p-AKT, STAT3 and p-STAT3 in X01 GSC infected with shCtrl, shMGAT4A-1, or shMGAT4A-2 lentivirus. GAPDH was used as a loading control. (I) IB analysis of MGAT4A, EGFR, ERK1/2, p-ERK1/2, AKT, p-AKT, STAT3, and p-STAT3 in 83 GSC infected with MGAT4A or vector-control lentivirus. GAPDH was used as a loading control.

The treatment with apoptosis inhibitors can significantly rescue the apoptosis and proliferation caused by the knockdown of MGAT4A (Figure S3E–G). Additionally, knockdown of MGAT4A led to a decrease in EGFR expression, which in turn resulted in reduced p-ERK1/2 (Figure 3A). To further elucidate the molecular mechanisms underlying this MGAT4A-driven signaling pathway, we investigated the expression levels of downstream proteins by using immunohistochemistry in GSC orthotopic mouse tumor tissues. Quantitative analysis revealed significant molecular alterations in MGAT4A-knockdown tumors compared to controls:

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 3 | Knockdown of MGAT4A induces GSC apoptosis by inhibiting EGFR-ERK1/2 signaling. (A) IB analysis of MGAT4A, EGFR, ERK1/2, p-ERK1/2, Caspase3, c-Caspase3 (cleaved-Caspase3), PARP and c-PARP (cleaved-Caspase3) in X01, 448 and GSC924 GSCs infected with shCtrl, shMGAT4A-1, or shMGAT4A-2 lentivirus. GAPDH was used as a loading control. (B) Apoptosis assay of X01 and 448 GSCs infected with shCtrl, shMGAT4A-1, or shMGAT4A-2 lentivirus. (C) IHC analysis of MGAT4A, Ki67, cleaved-Caspase3, EGFR, and p-ERK1/2 in orthotopic xenografts of X01-luc GSC infected with shCtrl, shMGAT4A-1, or shMGAT4A-2 lentivirus. Scale bar, 100 μm. (D) Kaplan–Meier survival curves for all glioma patients with MGAT4A and EGFR expression in the CGGA dataset. $P < 0.0001$, log-rank test.

MGAT4A, Ki67, EGFR, and p-ERK1/2 levels were substantially reduced, whereas cleaved-Caspase3 expression exhibited marked elevation (Figure 3C). To further explore the clinical relevance, we investigated the correlation between MGAT4A and EGFR expression with patient survival using the CGGA all glioma dataset. The data showed a notably poorer prognosis in glioma patients with concurrent high levels of MGAT4A and EGFR expression, as contrasted with other groups. (Figure 3D, CGGA all glioma, optimal cutoff, MGAT4A high EGFR high vs MGAT4A low EGFR low, $p < 0.0001$, log-rank test). These findings suggest that MGAT4A regulates GSC apoptosis through the EGFR-ERK1/2 signaling pathway, and elevated expression of both EGFR and MGAT4A negatively impacts the survival of GBM patients.

2.5 | MGAT4A Regulates GSC Invasion, Proliferation, and Self-Renewal Capacity through Its Interaction With EGFR

Based on the above results and mass spectrometry analysis (Figure S4A), we hypothesized that MGAT4A may interact with EGFR to regulate apoptosis and influence downstream ERK1/2 phosphorylation, which are involved in GSC invasion and tumorigenic capabilities. For validating the hypothesis, co-immunoprecipitation (co-IP) assay was conducted on 83 GSC infected with Flag-MGAT4A or vector lentivirus. The results confirmed the interaction between endogenous EGFR and exogenous MGAT4A (Figure 4A,B). To further validate these findings, we performed a co-IP assay in 293T cells involving the overexpression of EGFR or Flag-MGAT4A. The co-IP analysis with Flag antibody validated the interactions between MGAT4A and EGFR (Figure 4C). Additionally, to identify the direct interaction sites between MGAT4A and EGFR, we introduced point mutations at the N603 and N604 loci of EGFR, based on our sequencing data, and examined their effects on the interaction in 293T cells. The results demonstrated that the N604 mutation of EGFR inhibited the binding between EGFR and MGAT4A (Figure 4C). Next, we also evaluated the impact of EGFR mutations on GSC and downstream pathways. We overexpressed wild-type EGFR (EGFR-WT), N603 mutant (EGFR-N603) or N604 mutant (EGFR-N604) in X01 GSC with MGAT4A knockdown (Figure S4B). The results indicated that overexpression of EGFR-WT and EGFR-N603 largely restored the p-ERK1/2 level in the context of MGAT4A knockdown. However, the EGFR-N604 mutant failed to rescue the p-ERK1/2 signal to the same extent as EGFR-WT, providing strong evidence that the N604 site plays a crucial role in EGFR-ERK1/2 signaling.

These results prompted us to investigate which region of MGAT4A interacts with EGFR. To address this, we constructed various MGAT4A deletion fragments (Figure S4C). Co-IP results revealed that the EGFR binding region is positioned at the

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 4 | MGAT4A regulates GSC invasion, proliferation, and self-renewal capacity through its interaction with EGFR. (A) Co-IP analysis for the interaction of MGAT4A and EGFR in 83 GSC transfected with MGAT4A. Cell lysates were precipitated with anti-Flag antibody. (B) Co-IP analysis for the interaction of MGAT4A and EGFR in 83 GSC transfected with MGAT4A. Cell lysates were precipitated with the EGFR antibody. (C) Co-IP analysis for the interaction of MGAT4A and EGFR-mut in 293T cells transfected with MGAT4A and vector or EGFR-mut. Cell lysates were precipitated with anti-Flag antibody. (D–K) IB analysis of MGAT4A, EGFR, ERK1/2, p-ERK1/2, Caspase3, c-Caspase3, PARP, and c-PARP in X01 (D) and 448 (H) GSCs infected with shCtrl, shMGAT4A, or shMGAT4A+EGFR lentivirus. GAPDH was used as a loading control. RT-qPCR analysis of MGAT4A or EGFR mRNA expressions in X01 (E,F) and 448 (I,J) GSCs infected with shCtrl, shMGAT4A, or shMGAT4A+EGFR lentivirus. Data are presented as mean ± SEM ($n = 3$). Invasion assays with X01 (G) and 448 (K) GSCs infected with shCtrl, shMGAT4A, or shMGAT4A+EGFR lentivirus. Images taken after 48 h of invasion are representative of three independent experiments (scale bar, 50 μm), and (right) the graph shows the mean number of invasive cells ± SEM ($n = 3$). (L–O) Cell proliferation assays were performed using X01 (L) and 448 (N) GSCs infected with shCtrl, shMGAT4A, or shMGAT4A+EGFR lentivirus. Data are presented as mean ± SEM ($n = 3$). Limiting dilution assays in X01 (M) and 448 (O) GSCs infected with shCtrl, shMGAT4A, or shMGAT4A+EGFR lentivirus. Data are presented as mean ± SEM ($n = 24$). Significant results are presented as $^{*}p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$, $^{****}p < 0.0001$, by two-tailed Student's *t*-test.

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

N-terminal of MGAT4A (Figure S4D). To further explore the EGFR's downstream function on the MGAT4A signaling axis, we performed rescue experiments by ectopically overexpressing EGFR in MGAT4A knockdown GSCs (Figure 4D–F,H–J). These experiments showed that EGFR overexpression effectively rescued GSC invasion, proliferation, and self-renewal capacity (Figure 4G,K–O). Taken together, these findings indicate the involvement of MGAT4A in EGFR interactions, and the N604 mutation of EGFR inhibits its binding to MGAT4A. Furthermore, EGFR plays a critical role in the MGAT4A-mediated signaling pathway that regulates GSC invasion, proliferation, and self-renewal capacity.

2.6 | The Protein N-Glycosylation Inhibitor Tunicamycin Suppresses GSC Invasion and Tumor Progression

MGAT4A, a key member of the N-acetylglucosamine transferase family, is primarily localized in the Golgi apparatus and the rough endoplasmic reticulum, where it participates in N-glycosylation modification following protein synthesis. To further investigate whether changes in protein N-glycosylation could serve as a viable strategy for treating GBM and whether it can achieve the downstream signal suppression effect consistent with MGAT4A knockdown, we treated X01, 448, and GSC924 GSCs, along with MGAT4A-overexpressing 83 and 131 GSCs, with the protein N-glycosylation inhibitor tunicamycin. After 24 h of inhibitor treatment, we analyzed the changes in protein N-glycosylation using lectin blotting. These results indicate that, compared with vehicle control, the intracellular protein N-glycosylation levels in X01, 448, and GSC924 GSCs treated with tunicamycin significantly decreased in a concentration-dependent manner (Figure 5A). After the ectopic overexpression of MGAT4A in 83 and 131 GSCs, the protein N-glycosylation level was significantly increased. However, when treated with tunicamycin, this N-glycosylation level was reduced, indicating that tunicamycin effectively inhibits protein N-glycosylation in GSCs (Figure 5A). Moreover, flow cytometry showed that GSC apoptosis was promoted with increasing concentrations of tunicamycin (Figure 5B). Subsequently, we examined whether downregulation of protein N-glycosylation affected cell proliferation in GSCs. The growth of X01, 448, and GSC924 GSCs treated with tunicamycin was significantly inhibited in a concentration-dependent manner (Figure 5C–E). Similarly, 83 and 131 GSCs with ectopic MGAT4A overexpression also exhibited the same trend (Figure 5F,G). Additionally, we confirmed that the N-glycosylation inhibitor tunicamycin regulates apoptosis and the EGFR-ERK1/2 signaling pathway in GSCs. Treatment with tunicamycin increased the levels of cleaved-Caspase3 and cleaved-PARP, while decreasing the expression of both EGFR and p-ERK1/2 (Figure 5H,I).

Furthermore, we evaluated the ability of tunicamycin to inhibit the tumor development of GSC in vivo. Orthotopic X01 GSC-bearing mice received intraperitoneal injections of tunicamycin (0.5 mg kg^{-1}) weekly for 3 weeks. Daily monitoring of mice enables us to assess the survival rate of xenografts after tunicamycin treatment. The results indicated that survival in xenograft mice treated with tunicamycin was significantly prolonged compared with the control group (Figure 5J). Interestingly, the control group mice exhibited myelin-related infiltration in the corpus callosum, and significant invasion extending into the opposite hemisphere, whereas the tunicamycin-treated group experienced a decrease in such invasion (green box, Figure 5K). Furthermore, immunohistochemical staining revealed that tunicamycin treatment decreased the expression of Ki67, EGFR, and p-ERK1/2, while increasing the expression of cleaved-Caspase3 (Figure 5L). In conclusion, these results indicate that the phenotype induced by tunicamycin is consistent with that caused by specific inhibition of MGAT4A, further reinforcing the conclusion that N-glycosylation plays a crucial role in the maintenance of GSCs. This suggests that inhibition of N-glycosylation could be a promising direction for tumor treatment.

2.7 | Targeted Delivery of Cas9/sgMGAT4A Using Tumor-Penetrating Nanocapsules Reduces GSC Invasion and Tumor Progression

Although tunicamycin, as a broad-spectrum N-glycosylation inhibitor, has a significant tumor suppressive effect, it does not demonstrate the therapeutic potential of MGAT4A as a specific target. To evaluate the potential of MGAT4A as a therapeutic target for GBM, we developed CRISPR/Cas9 ribonucleoprotein (RNP)-based nanocapsules with ApoE-decorated, termed "ApoE-NP-Cas9/sgRNA" for MGAT4A gene editing, as previously reported [15, 56, 57] (Figure 6A). We first characterized the nanocapsules (Figure S5A–D), and the data showed that the average diameter of the ApoE-NP-Cas9/sgRNA was 43.8 nm, with a narrow size distribution (polydispersity index, PDI = 0.243), indicating good dispersibility (Figure 6B; Figure S5A,B). Transmission electron microscopy (TEM) imaging confirmed this, showing that the size of the spherical nanocapsules was consistent with the DLS data (Figure S5D). The zeta potential measurement value was + 0.56 mV (Figure S5C), indicating that the surface charge was close to neutral, which is beneficial for reducing non-specific interactions with serum proteins to enhance the stability of nanocapsules. To assess its serum stability, we incubated the nanocapsules in fetal bovine serum for 48 h. The change in particle size was negligible, demonstrating excellent serum stability (Figure S5E). ApoE shows a strong affinity for low-density lipoprotein receptors (LRPs), which are abundant on the surface of both blood-brain barrier (BBB) endothelial cells and GBM cells (Figure S5F), making it an effective ligand for glioma targeting [58]. The transwell model of the in vitro BBB also proved this point. ApoE-NP-Cas9/sgRNA showed a 2.7-fold better transport ratio than free-Cas9/sgRNA and a 2.1-fold better ratio compared to non-targeted NP-Cas9/sgRNA (Figure S5G,H). The pharmacokinetic results indicated that the half-life ($t_{1/2}$) of the ApoE-NP-Cas9/sgRNA group in the blood circulation was 42 min (Figure S5I). In contrast, free Cas9/sgRNA was eliminated quickly from the bloodstream ($t_{1/2}$ = 17 min), indicating that the nanocapsules play a crucial role in protecting Cas9/sgRNA from enzymatic degradation. In conclusion, the above data suggest that ApoE-NP-Cas9/sgRNA nanocapsules exhibit excellent targeting ability and blood stability.

Next, we evaluated the therapeutic efficacy of ApoE-NP-Cas9/sgRNA both in vitro and in vivo. T7E1 analyses showed the ApoE-NP-Cas9/sgMGAT4A led to a high gene editing frequency of 53.7% in X01 and 76.9 % in 448 GSCs (Figure 6C). ApoE-NP-Cas9/sgMGAT4A notably decreased invasion in both X01 and 448

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 5 | The protein N-glycosylation inhibitor tunicamycin suppresses GSC invasion and tumor progression. (A) Lectin blot analysis the protein N-glycosylation of X01, 448, and GSC924 GSCs, and overexpressing MGAT4A 83, 131 GSCs treatment with tunicamycin. GAPDH was used as a loading control. (B) Apoptosis assay of X01 and 448 GSCs treated with tunicamycin. (C–E) Cell proliferation assays performed using X01 (C), 448 (D), and GSC924 (E) GSCs treated with tunicamycin. Data are presented as mean ± SEM ($n = 3$). (F,G) Cell proliferation assays performed using overexpression MGAT4A and treatment with tunicamycin in 83 and 131 GSCs. Data are presented as mean ± SEM ($n = 3$). (H) IB analysis of MGAT4A, EGFR, ERK1/2, p-ERK1/2, Caspase3, c-Caspase3, PARP and c-PARP in X01, 448, and GSC924 GSCs with tunicamycin treatment. GAPDH was used as a loading control. (I) IB analysis of MGAT4A, EGFR, ERK1/2, p-ERK1/2, Caspase3, c-Caspase3, PARP, and c-PARP in overexpressing MGAT4A 83 and 131 GSCs with tunicamycin treatment. GAPDH was used as a loading control. (J) Kaplan–Meier survival curves of mice implanted with X01 GSC and treated with vehicle-control or tunicamycin ($n = 8$, 5×10^4 cells/mouse). (K) H&E staining of the whole brains of mice bearing orthotopic xenografts of X01 GSC and treated with vehicle-control or tunicamycin. Scale bar, 100 μm. (L) IHC analysis of Ki67, cleaved-Caspase3, EGFR, and p-ERK1/2 in orthotopic xenografts of X01 GSC treated with vehicle-control or tunicamycin. Scale bar, 100 μm. Significant results are presented as $^{**}p < 0.01$, $^{***}p < 0.001$, $^{****}p < 0.0001$, by two-tailed Student's *t*-test or log-rank test.

GSCs compared with ApoE-NP-Cas9/sgScramble (Figure 6D,E). Furthermore, MGAT4A protein levels, along with downstream proteins such as EGFR and p-ERK, were markedly reduced, while apoptosis-associated proteins, including cleaved-Caspase3 and cleaved-PARP, were elevated in MGAT4A-edited X01 and 448 GSCs (Figure 6F). Additionally, ApoE-NP-Cas9/sgMGAT4A treatment inhibited growth and self-renewal capacity in X01 and 448 GSCs (Figure S5J-M).

Furthermore, we evaluated the effectiveness of ApoE-NP-Cas9/sgMGAT4A in inhibiting the progression of GSC in vivo. The mice, which had been implanted with orthotopic X01-luc GSC, received either nanocapsules or PBS intravenously every other day, with the injections spanning a total of 10 days (Figure 6A), and tumor bioluminescence intensity and survival were monitored. Mice treated with ApoE-NP-Cas9/sgMGAT4A showed significant tumor inhibition compared to the ApoE-NP-Cas9/sgScramble and PBS groups (Figure 6G). Notably, MGAT4A gene editing via nanocapsules significantly prolonged survival (Figure 6H). Throughout the treatment period, no significant weight loss was observed in mice treated with ApoE-NP-Cas9/sgMGAT4A nanocapsules compared to ApoE-NP-Cas9/sgScramble and PBS (Figure S5N). T7E1 analyses showed the ApoE-NP-Cas9/sgMGAT4A led to a 9.6% gene

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 6 | Legend on next page.

editing frequency, and the MGAT4A protein level was remarkably reduced in mice injected with ApoE-NP-Cas9/sgMGAT4A (Figure S5O,P). Additionally, tumor volume in the ApoE-NP-Cas9/sgMGAT4A-treated group was markedly reduced (red box), with no observed invasion to the opposite hemisphere via the corpus callosum (green box), in contrast to the ApoE-NP-Cas9/sgScramble and PBS groups (Figure 6I).

Finally, we evaluated the safety of the nanocapsules. At 1, 7, and 14 days after the injection of nanocapsules, blood biochemical

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

parameters, body weight, and changes in liver and kidney cytokine levels were monitored in BALB/c healthy mice treated with ApoE-NP-Cas9/sgRNA or PBS. The results indicated that mice treated with ApoE-NP-Cas9/sgRNA nanocapsules had similar hematological and biochemical profiles to those in mice treated with PBS throughout the treatment course (Figure S6A–G). Additionally, the mice maintained their body weight, and no significant changes were observed in pro-inflammatory cytokine expression (IL-6, TNF-α, and IL-1β) in liver and kidney tissues (Figure S6H–J). These findings suggest the safety of ApoE-NP-Cas9/sgRNA and that it does not cause immune toxicity.

In summary, these results demonstrate that MGAT4A gene editing mediated by nanocapsules exhibits excellent biological safety and significantly reduces tumorigenicity in vivo, highlighting the potential of MGAT4A as a therapeutic target for invasive GBM.

3 | Discussion

The presence of GSCs and their strong invasiveness are key factors contributing to incomplete surgical resection, drug resistance during tumor radiotherapy and chemotherapy, and tumor recurrence. To address the challenge posed by GSC invasiveness in brain tumor treatment, we identified MGAT4A as a potential biomarker involved in both GSC invasion and protein glycosylation through sequencing analysis. High MGAT4A expression was found to be significantly associated with poor patient prognosis. While many studies have highlighted the role of MGAT4A in regulating invasion in various cancers, the specific relationship between MGAT4A and GSCs, as well as the underlying molecular mechanisms, remains largely underexplored. Our study demonstrated that depletion of MGAT4A expression suppressed invasion, proliferation, and tumorigenic potential in invasive GSCs. Xenograft mouse model results further showed that MGAT4A knockdown significantly inhibited GSC invasion and improved survival rates. Overall, the expression of MGAT4A is strongly linked to GSC invasion, tumorigenesis, and poor prognosis in glioma patients. As far as we know, this study is the first to establish MGAT4A as a crucial regulator of GSC invasiveness both in vitro and in vivo.

N-acetylglucosaminyltransferases are a group of enzymes responsible for the synthesis and modification of N-glycans, primarily located in the Golgi apparatus. These enzymes are categorized into several isoforms based on their specific functions, including GnT-I, GnT-II, GnT-III, GnT-IV, GnT-V, GnT-VI, and GnT-IX [34–37]. They catalyze the addition of N-acetylglucosamine to the core pentasaccharide of N-glycans, facilitating the formation of branched N-glycan structures on glycoproteins [32]. These enzymes have been shown to play a crucial role in the invasion and metastasis of tumor cells through the extension of N-glycan branching [31, 33]. MGAT4A, a key glycosyltransferase, is essential for catalyzing the formation of complex polysaccharide structures [41, 42]. However, the effects of MGAT4A-mediated glycosylation on downstream targets and the biological behavior of GSCs remain largely unexplored. Through protein N-glycosylation mass spectrometry sequencing analysis, we found that the loss of MGAT4A inhibited protein N-glycosylation levels, promoted cell apoptosis, and disrupted the downstream EGFR signaling pathway.

EGFR is a transmembrane glycoprotein and a member of the ERBB/HER receptor tyrosine kinase family, playing a key role in cell proliferation and signal transduction [53]. Abnormally elevated EGFR is associated with most common human solid tumors including glioblastoma [54, 55], kidney cancer [59], lung cancer [60], prostate cancer [61], pancreatic cancer [55, 62], and breast [63], where it contributes to tumor growth, angiogenesis, invasion, metastasis, and resistance to apoptosis [64]. We discovered that MGAT4A interacts with EGFR and modulates its function by catalyzing the N-glycosylation of the N604 site on EGFR, which in turn affects the phosphorylation of downstream ERK1/2. EGFR is extensively modified by N-linked glycosylation, and it has been reported that deglycosylation of EGFR leads to reduced expression and impaired cell surface transport, thereby regulating the proliferation of CRC cells [64]. However, the specific N-glycosylation sites that are altered in this process remain unclear. Our results indicate that MGAT4A catalyzes N-glycosylation at the EGFR N604 site. Interestingly, deletion of the MGAT4A N-terminus prevents its interaction with EGFR, suggesting that the N-terminal structure is essential for MGAT4A binding to EGFR and exerting its catalytic effects. Furthermore, EGFR activates the RAF-MAPK/ERK kinase (MEK)-ERK1/2 signaling cascade through RAS activation. Once activated, ERK1/2 phosphorylates a wide range of downstream substrates, translocating to the nucleus to modulate various proteins and transcription factors that regulate cell proliferation, survival, and metabolism [54, 60, 64]. These findings corroborate our results, demonstrating that MGAT4A regulates the EGFR-ERK1/2 signaling pathway by modulating EGFR expression and N-glycosylation, thereby controlling GSC invasion, proliferation, and tumorigenesis.

FIGURE 6 | Targeted delivery of Cas9/sgMGAT4A using tumor-penetrating nanocapsules reduces GSC invasion and tumor progression. (A) Schematic illustration of ApoE-NP-Cas9/sgRNA nanocapsule preparation and orthotopic therapy. Created with BioRender.com. (B) Size distribution of ApoE-NP-Cas9/sgRNA nanocapsules. (C) Indel detection by T7 endonuclease 1 (T7E1) of X01 and 448 GSCs treated by ApoE-NP-Cas9/sgMGAT4A. (D,E) Invasion assays with X01 and 448 GSCs treated with ApoE-NP-Cas9/sgMGAT4A and ApoE-NP-Cas9/sgScramble. (D) Images taken after 48 h of invasion are representative of three independent experiments (scale bar, 50 μm; $n = 3$), and (E) the graph shows the mean number of invasive cells ± SEM. (F) IB analysis of MGAT4A, EGFR, ERK1/2, p-ERK1/2, Caspase3, c-Caspase3, PARP and c-PARP in X01 and 448 GSCs treatment with ApoE-NP-Cas9/sgMGAT4A, ApoE-NP-Cas9/sgScramble or PBS. GAPDH was used as a loading control. (G) Luminescence images of orthotopic X01-luc human glioblastoma tumor-bearing nude mice following treatment with ApoE-NP-Cas9/sgMGAT4A, ApoE-NP-Cas9/sgScramble, or PBS. (H) Kaplan–Meier survival curves of mice implanted with 1×10^4 X01-luc GSCs and treated with ApoE-NP-Cas9/sgMGAT4A, ApoE-NP-Cas9/sgScramble, or PBS ($n = 6$ in each group). PBS versus sgMGAT4A, $p = 0.0006$, sgScramble versus sgMGAT4A, $p = 0.0005$, log-rank test. (I) H&E staining of the whole brains of mice bearing orthotopic xenografts of X01-luc GSCs and treated with ApoE-NP-Cas9/sgMGAT4A, ApoE-NP-Cas9/sgScramble, or PBS. Scale bar, 100 μm. Significant results are presented as $^{**}p < 0.01$, $^{***}p < 0.001$, by two-tailed Student's *t*-test or log-rank test.

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

To further investigate the impact of protein N-glycosylation on GSCs, we treated them with tunicamycin, a known protein N-glycosylation inhibitor [65]. Our results demonstrate that tunicamycin significantly suppresses EGFR expression and phosphorylation of downstream ERK1/2, leading to reduced cell invasion and proliferation while promoting apoptosis both in vitro and in vivo. Previous research has shown that the conformational stability of EGFR is, at least in part, regulated by N-linked glycosylation [66]. Deglycosylation-induced instability of protein conformation can impair EGFR function by preventing its proper folding, thus compromising its functional capacity [66]. Specifically, tunicamycin induces the production of an immature 130–135 kDa form of EGFR that fails to localize to the cell surface and cannot bind EGF [64]. These findings, along with prior evidence that glycosylation regulates EGFR signaling [64], underscore the essential role of protein N-glycosylation in tumor progression. These observations suggest that inhibiting protein glycosylation could be a promising therapeutic strategy for cancer treatment. While tunicamycin, a broad-spectrum N-glycosylation inhibitor, shows therapeutic potential, its specific targeting effects are limited. The specific organ targeting of nanoparticles is playing an increasingly important role in drug delivery [67]. Based on this, we engineered ApoE-NP-Cas9/sgRNA nanocapsules, enabling intravenous administration to selectively edit the MGAT4A gene in brain tumors, as previously reported [15, 56, 58]. The ApoE coating allows the nanocapsules to cross the BBB and target tumor cells. Upon internalization by GBM cells, the elevated glutathione (GSH) levels in the tumor microenvironment induce site-specific disulfide bond cleavage, enabling the localized release of Cas9/sgMGAT4A. Our results demonstrate that ApoE-NP-Cas9/sgMGAT4A nanocapsules significantly reduce tumorigenicity and prolong the survival of mice. Nanoparticle-based medicines offer a promising solution to overcome the limitations of free anti-tumor drugs, such as poor safety and efficacy, inability to target tumor cells, and short circulation time. However, clinical translation still faces challenges, including the inability of preclinical tumor models to fully simulate the complex pathological features of patient tumor tissues, as well as issues related to production processes, industrial-scale manufacturing, and batch-to-batch quality control [68]. Nevertheless, it is undeniable that as more nanomedicines are approved for clinical use and trials, this method of targeting MGAT4A through intravenous injection of nanocapsules provides a promising strategy for future clinical applications in cancer therapy.

In conclusion, our study demonstrates that MGAT4A regulates GBM invasion and tumorigenesis through the EGFR-ERK1/2 signaling pathway. Suppressing MGAT4A or inhibiting abnormal protein N-glycosylation significantly extended the survival of mice with orthotopic GBM. These findings highlight MGAT4A as a potential molecular diagnostic marker for personalized GBM therapies, offering a promising new therapeutic approach to combat this highly invasive disease.

4 | Experimental Section

4.1 | Cell Culture

The human GSCs X01 [69], 448 [70], GSC924 [71], 131 [72], and 83 [73] were obtained from collaborators or by ourself, as previously described [14, 15]. All GSCs were cultured in full GSC medium, including DMEM/F12 medium (Gibco), EGF (20 ng mL^{-1}; R&D Systems), bFGF (10 ng mL^{-1}; R&D Systems), B27 supplement (Invitrogen), and 1 % penicillin/streptomycin (P/S; HyClone). Additionally, HA1800 (ScienCell Research Laboratory, USA) and 293T (ATCC, Manassas, Virginia, USA) cells, were grown in high-glucose DMEM (Gibco) supplemented with 10% FBS (HyClone), 1% P/S and 1% non-essential amino acids (Gibco). All cultures were kept at 37°C in a humidified 5% CO_2 incubator and routinely tested for mycoplasma contamination.

4.2 | Plasmids

To engineer lentiviral constructs for shRNA expression targeting MGAT4A, annealed oligomers were inserted into AgeI-EcoRI-digested pLKO.1-lentiviral vectors sourced from Addgene. The specific shRNA sequences employed were: shMGAT4A-1, 5′-CCAGTCAATGTAGAAAGTTAT-3′; shMGAT4A-2, 5′-CCGGATCTTACTCTGATTGTA-3′. For overexpression and co-immunoprecipitation (co-IP) studies, GV703-Flag-MGAT4A was subcloned using the GV703 vector from Genechem. The MGAT4A PCR-amplified oligomers included the sense primer 5′-AGGTCGACTCTAGAGGATCCCGCCACCATGAGGCTCCGCA ATGGAAC-3′ and antisense primer 5′-TCCTTGTAGTCCATG GATCCGTTGGTGGCTTTTTTAATATGAATCTCATTAAG-3′.
The pCDH-EGFR construct was engineered for co-IP and overexpression studies, utilizing the pCDH-vector supplied by Genechem. The EGFR PCR-amplified oligomers included the sense primer, 5′- GCTCTAGAATGTACCCATACGATGTTCCAG ATTACGCTATGCGACCCTCCGGGAC-3′, and antisense primer, 5′-AAGGAAAAAAGCGGCCGCTCATGCTCCAATAAATT-3′.
These oligomers were sourced from Tsingke, based in Beijing, China. To ensure accuracy, all constructs underwent rigorous verification via DNA sequencing, also conducted by Tsingke.

4.3 | Lentivirus Production and Infection

The lentivirus was produced following previously established protocols [74]. In summary, approximately 3 to 4 million 293T cells were seeded into 100-mm culture dishes and allowed to incubate for 24 h. The cells were then co-transfected with a mixture of 4.5 μg of lentiviral plasmids (including pLKO-shCtrl, shMGAT4A-1, shMGAT4A-2, GV703-vector, GV703-Flag-MGAT4A, pCDH-vector, or pCDH-EGFR), 3 μg of psPAX2, and 1.5 μg of pMD2.G, along with 27 μL of lipofectamine 2000. Six hours post-transfection, the medium was refreshed, and then, 48 h later, the lentivirus-containing medium was collected. The viral particles were subsequently concentrated and purified utilizing a Lenti-X concentrator from Clontech. The cells were then infected with lentivirus in a solution containing 6 μg mL^{-1} polybrene.

4.4 | Reverse Transcription-Quantitative PCR (RT-qPCR)

Total RNA was extracted from GSCs using the FastPure Complex Tissue/Cell Total RNA Isolation Kit from Vazyme. Then, 1 μg of the total RNA was employed as the template to synthesize cDNA, which was achieved with the HiScript III All-in-one

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

RT SuperMix Perfect for qPCR Kit from Vazyme. To assess gene expression levels, quantitative RT-qPCR was conducted utilizing the Light Cycler 480II real-time detection system (Roche) along with Taq Pro Universal SYBR qPCR Master Mix from Vazyme. The levels of target gene expression were calibrated against hGAPDH. The primer sequences used were as follows: hGAPDH, forward 5′-GGAGTCCACTGGCGTCTTCAC-3′ and reverse 5′-GAGGCATTGCTGATGATCTTGAGG-3′; hMGAT4A, forward 5′-CAGCTGGGCTTCATTGGTAAA-3′ and reverse 5′-ATGGTCCAGGAGCCAATCAA-3′; hEGFR, forward 5′-CAGATCGCAAAGGGCATGAA-3′ and reverse 5′-TTGCCTCCTTCTGCATGGTA-3′.

4.5 | Immunoblot Analysis

Proteins were extracted using RIPA buffer supplemented with a complete set of protease inhibitors (Solarbio). Following extraction, the proteins were subjected to electrophoresis, then transferred onto PVDF membranes (Millipore) for further analysis. To prevent non-specific binding, the membranes were blocked with a 5% skim milk solution (Epizyme Biotech). They were then incubated overnight at 4°C with various primary antibodies, including those targeting MGAT4A (1:1000, Abnova), EGFR (1:1000, Proteintech), ICAM1 (1:1000, Cell Signaling Technology), M6PR (1:1000, Sangon Biotech), Flag (1:1000, Cell Signaling Technology), ERK1/2 (1:1000, Beyotime), p-ERK1/2 (1:1000, Beyotime), AKT (1:1000, Cell Signaling Technology), p-AKT (1:1000, Cell Signaling Technology), STAT3 (1:1000, Cell Signaling Technology), p-STAT3 (1:1000, Cell Signaling Technology), Caspase3 (1:1000, Cell Signaling Technology), cleaved-Caspase3 (1:1000, Cell Signaling Technology), PARP (1:1000, Cell Signaling Technology), cleaved-PARP (1:1000, Cell Signaling Technology), and GAPDH (1:1000, Sangon Biotech). To visualize the immunoreactive bands, peroxidase-labeled affinity purified secondary antibodies (Sangon Biotech) were employed alongside an ECL detection reagent (Epizyme Biotech) or the Amersham Image 680 detection system (GE Healthcare).

4.6 | Lectin Blot Analysis

The protein extraction process is the same as immunoblot analysis. Proteins sample are separated via electrophoresis, transferred onto PVDF membranes (Millipore), and blocked. The membranes are incubated with primary antibodies against L-PHA (1:1000, Vector Laboratories) overnight at 4°C. The immunoreactive bands are visualized by using horseradish peroxidase avidin D (Av-HRP) (Vector Laboratories), the ECL detection reagent (Epizyme Biotech), or the Amersham Image 680 detection system (GE Healthcare).

4.7 | Cell Proliferation Assay

GSCs were seeded at a density of 10^3 cells/well in 96-well plates with full GSC medium. The absorbance of viable cells was measured using the Cell Counting Kit-8 (CCK-8) Assay Kit (US EVER-BRIGHTINC). For the protein N-glycosylation inhibitor study, 50 nM, 300 and 600 nM of tunicamycin (with DMSO added as a vehicle) treated GSC 1 day after seeding. The absorbance was detected by a SpectraMaxi3x Microplate Reader (Molecular Devices). Cell viability was determined from the absorbance of the extracellular medium at 450 nm. The results were analyzed and presented visually using Prism 8.3.

4.8 | Limiting Dilution Assay (LDA)

For in vitro LDA, GSCs were seeded at diminishing densities (100, 50, 25, and 5 cells/well) in 96-well plates filled with full GSC medium. The capacity to form tumorspheres was ascertained by counting the wells that did not have any tumorspheres following a 5–7 days incubation period. The results of the LDA were analyzed using ELDA website, available at http://bioinf.wehi.edu.au/software/elda/.

4.9 | Invasion Assay

Transwell chambers from LABSELECT were coated with Matrigel Basement Membrane Matrix by BD. GSCs were suspended in DMEM/F12 medium and seeded into the upper chamber at a density of 4×10^4 cells per well. The full GSC medium for GSCs was placed in the lower chamber. After incubating at 37°C for 24–48 h, the chamber was soaked in 4% paraformaldehyde (Servicebio) and stained with crystal violet (Solarbio) to fix and stain the GSCs that had invaded the lower chamber. Then, they were observed under bright-field microscopy. The invading cells were determined by counting the cells in three separate microscopic fields per well.

4.10 | Protein Extraction and Sample Preparation

Collect 83 GSC infected with MGAT4A-overexpression and vector-control lentivirus for protein extraction. An equal volume of lysis buffer (8 M urea; 1 % protease inhibitor) was added to each sample. Then, ultrasonic lysis and centrifugation were carried out. Transferred supernatant to a new tube, measured protein concentration with the BCA kit (Vazyme). Took an equal quantity of each sample for enzymatic hydrolysis, adjusted volume with lysis solution. Slowly added 20% TCA, vortexed, and precipitate at 4°C for 2 h. After centrifuging at 4500 g for 5 min and washing twice with pre-cooled acetone, the precipitate was collected. Added TEAB to pellet to 200 mM final concentration after drying and ultrasonically dispersed. Added trypsin at 1:50 ratio (protease: protein, m/m), hydrolyzed overnight. Added dithiothreitol (DTT) to 5 mM final concentration, incubated at 56°C for 30 min. Then added iodoacetamide (IAA) to 11 mM final concentration, incubated for 15 min at room temperature in the dark. Dissolve the peptide in the IP buffer, mix with N-glycosylated resin (item 23263910488716510, Hangzhou Jingjie), and shake on a 4°C shaker overnight. Wash with lysis buffer and water, elute with 0.1% TFA, collect, desalinate with C18 ZipTips, and proceed with LC/MS analysis.

4.11 | LC-MS/MS Analysis

Peptides were dissolved in a 0.1% formic acid/2% acetonitrile aqueous solution and separated by UPLC (ultra performance

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

liquid chromatography) on an EASY-nLC 1000 system. Gradient elution was used with a flow rate of 500 nL min^{-1}. Analysis via mass spectrometry in Q Exactive Plus involved a primary mass scan range of 350–1800 $m\ z^{-1}$ and secondary scan from 100 $m\ z^{-1}$. The data dependency scanning mode selected high signals for fragmentation, using 28% energy and an automatic gain control of 5×10^4. Signal threshold was 5×10^3 ions s^{-1}, and max injection time was 200 ms with 15 s dynamic exclusion to prevent ion redundancy.

4.12 | Co-Immunoprecipitation (co-IP)

In co-IP experiments, 83 GSC and 293T cells with exogenous overexpression MGAT4A or EGFR were washed twice with PBS, followed fixation with 1 mM DSP, lysis with IP buffer (Thermo Fisher Scientific), and centrifuging at 13,000 rpm for 20 min in 4°C. Keep 40 μL protein lysate was used as input, rest mixed with A/G Dynabeads (Thermo Fisher Scientific) preincubated with the indicated antibody or Flag-Magnetic (Bimake) at 4°C overnight. Beads were washed 4–5 times with IP buffer and then the immunoprecipitates were boiled for 10 min at 95°C with IP buffer and loading buffer (Epizyme Biotech) for immunoblotting.

4.13 | Apoptosis Assay

To assess apoptosis, GSCs were seeded into 60 mm dishes at a density of 5×10^5 cells per dish and cultured for 24 h. Following this, the cells were infected with lentivirus for 6 h and the medium was refreshed. The cells were cultured for 48 h, then the GSCs were collected, washed with PBS, and incubated with Annexin V-FITC and propidium iodide (PI) (Beyotime). For the protein N-glycosylation inhibitor study, 50 nM, 300 and 600 nM of tunicamycin (with DMSO added as a vehicle) was treated to the cell for 24 h, collected the GSCs, and followed the above steps for staining. Subsequently, the stained cells were gathered, and the fluorescence was quantified in accordance with the manufacturer's instructions using a BD FACSAria III flow cytometer and FlowJo v10 software.

4.14 | Mouse Model

In compliance with the approved protocols by the Animal Care and Use Committee at the Laboratory Animal Center, Henan University (HUSOM2021-0105), the study employed mice sourced from Beijing Vital River Laboratory Animal Technology Co. Ltd. These mice were randomly assigned based on their body weight ahead of the experiments. For the establishment of the orthotopic mouse model, we resuspended 5×10^4 GSCs and carefully transplanted them into the left striatum of 5-week-old female BalB/c nude mice via stereotactic injection. The precise coordinates for the injection were 2.2 mm to the left of the midline, 0.2 mm behind the bregma, and at a depth of 3.5 mm. The mice were euthanized upon observing a 20% decrease in body weight, and their survival rates were analyzed using GraphPad PRISM software version (v8.3, CA, USA).

4.15 | In Vivo Imaging

In the orthotopic mouse model, all mice were randomized and divided into three groups based on their weight, and were injected with X01-luc GSC, which was infected with shCtrl, shMGAT4A-1, and shMGAT4A-2 lentivirus. We measured the luminescence levels in their brains on days 7, 14, 20, 22, 24, and 26, using an IVIS III instrument. The mice were put under anesthesia with isoflurane, and then a dose of 150 mg kg^{-1} (equivalent to 100 μL) of luciferin was administered via intraperitoneally. The measurements were taken 10 min after the luciferin injection, and the photons emitted from the brain area were analyzed using live imaging software.

4.16 | Histology and Immunohistochemistry (IHC)

For observation of histological features, the brains were taken out and fixed in 4% paraformaldehyde solution for a duration of 48 h. Once fixed, the brains were then embedded in paraffin and sliced at a 4 μm thickness with high-precision microtome (Leica RM2125 RTS, Leica Biosystems, Nussloch, Germany). These sections were then dyed using 1% hematoxylin from DaKo and 0.25% eosin from Merck. Once the staining was complete, the sections were sealed using neutral resin and left to air dry naturally.

For IHC staining, sections underwent antigen retrieval with citrate buffer, endogenous peroxidase blocking, then incubated overnight at 4°C in a humidified chamber with the primary antibody: MGAT4A (1:50, Abnova), cleaved-Caspase3 (1:200, Cell Signaling Technology), EGFR (1:250, Service), Ki67 (1:100, Beyotime), and p-ERK1/2 (1:100, Beyotime). Next, the tissue sections staining was performed using 3,3′-diaminobenzidine (DAB, Vector Laboratories) as the chromogen. Finally, the sections were viewed and photographed using the microscope slide scanners (Grundium OCUS40X, Grundium, Finland).

4.17 | Nanocapsule Materials

We developed Cas9/sgMGAT4A nanocapsules following the methods outlined in our earlier publication [15, 56]. The synthetic single guide RNA (sgRNA) designed to target the human MGAT4A and the scramble were produced by Tsingke Biotechnology Co. Ltd. (Beijing, China). The sequences of the sgRNAs were as follows: sgRNA-MGAT4A, 5′-GGGAATGAAGAGTTTCTATG-3′; sgRNA-Scramble, 5′-CACG GGCAGCTTGCCGG-3′.

4.18 | In Vitro Gene Editing

Seeded X01 or 448 GSCs in 6-well plates (1×10^5 cells/well), cultured 24 h. Incubated 12 h with ApoE-NP-Cas9/sgMGAT4A or ApoE-NP-Cas9/sgScramble (Cas9: 20 nM), added 1 mL fresh media/well, then incubated 48 h at 37°C. Extracted genomic DNA with Universal Genomic DNA Kit (CWBIO, China). Amplified sgRNA-targeted locus with 2 × Phanta Flash

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

Master Mix (Vazyme, China). The PCR primer sequences used were as follows: forward 5′-CCATTCATTTTTTAGTGTGA-3′ and reverse 5′-GCGTTTTTAAAAGCATATTC-3′. After gel extraction purification, performed T7E1 cleavage assays. Denatured and reannealed 100 ng purified PCR product in NEB buffer 2, added T7E1, incubated 1 h at 37°C, analyzed on 2% agarose gels, imaged with Amersham Image 680 detection system (GE Healthcare).

4.19 | Treatment With ApoE-NP-Cas9/sgRNA Nanocapsules

To evaluate the antitumor efficacy of ApoE-NP-Cas9/sgMGAT4A, we established X01-luc GSC orthotopic mouse model. The mice were randomly divided into three groups: PBS, ApoE-NP-Cas9/sgScramble, and ApoE-NP-Cas9/sgMGAT4A. Starting on day 30, the mice were given intravenous injections of PBS or nanocapsules every other day for five treatments. Kaplan–Meier survival curves generated for each group ($n = 6$); body weights measured throughout.

4.20 | Public Data Analysis

The Gravendeel and TCGA of GBM or all glioma dataset was downloaded from the Data Visualization Tools for Brain Tumor Datasets (GlioVis) data portal (http://gliovis.bioinfo.cnio.es/).

4.21 | Statistics and Reproducibility

The statistical analyses were carried out via GraphPad PRISM software (v8.3, CA, USA). The Kaplan–Meier approach was utilized to construct survival curves. Mouse experiment results of multiple datasets were compared by ANOVA with the log-rank test; two-dataset experiment results by two-tailed Student's *t*-test. $P < 0.05$ were regarded statistically significant; individual p values are provided in the figure legends. All experiments had three technical replicates for reproducibility.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (82173228). We thank the members of J. Yin's lab for technical support with the experimental procedures. We are also grateful to Xiong Jin and Rui Gong for their contributions to the bioinformatics analyses, and to Yilin Deng for assistance in preparing the graphical abstract. In addition, we thank Jingjie PTM Bio Inc. (Hangzhou, China) for support with the mass spectrometry analysis.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The raw N-glycosylation proteomic data have been deposited in the PRIDE database under accession number PXD052176.

References

1. Y. Patrick, M. D. Wen, and S. Kesari, "Malignant Glioma in Adults," *New England Journal of Medicine* 359, no. 5 (2008): 492–507.

2. R. Stupp, M. E. Hegi, W. P. Mason, et al., "Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial," *Lancet Oncology* 10, no. 5 (2009): 459–466, https://doi.org/10.1016/S1470-2045(09)70025-7.

3. K. D. Miller, Q. T. Ostrom, C. Kruchko, et al., "Brain and Other Central Nervous System Tumor Statistics, 2021," *CA: A Cancer Journal for Clinicians* 71, no. 5 (2021): 381–406.

4. M. Li, L. Lu, Q. Xiao, et al., "Bioengineer Mesenchymal Stem Cell for Treatment of Glioma by IL-12 Mediated Microenvironment Reprogramming and nCD47-SLAMF7 Mediated Phagocytosis Regulation of Macrophages," *Exploration (Beijing)* 4, no. 6 (2024): 20240027, https://doi.org/10.1002/EXP.20240027.

5. A. Claes, A. J. Idema, and P. Wesseling, "Diffuse Glioma Growth: A Guerilla War," *Acta Neuropathologica* 114, no. 5 (2007): 443–458, https://doi.org/10.1007/s00401-007-0293-7.

6. F. B. Furnari, T. Fenton, R. M. Bachoo, et al., "Malignant Astrocytic Glioma: Genetics, Biology, and Paths to Treatment," *Genes & Development* 21, no. 21 (2007): 2683–2710, https://doi.org/10.1101/gad.1596707.

7. T. Chouleur, M. L. Tremblay, and A. Bikfalvi, "Mechanisms of Invasion in Glioblastoma," *Current Opinion in Oncology* 32, no. 6 (2020): 631–639, https://doi.org/10.1097/CCO.0000000000000679.

8. A. Vollmann-Zwerenz, V. Leidgens, G. Feliciello, et al., "Tumor Cell Invasion in Glioblastoma," *International Journal of Molecular Sciences* 21, no. 6 (2020): 1932, https://doi.org/10.3390/ijms21061932.

9. S. Zhang, B. S. Zhao, A. Zhou, et al., "m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-Like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program," *Cancer Cell* 31, no. 4 (2017): 591–606.e6, https://doi.org/10.1016/j.ccell.2017.02.013.

10. S. Bao, Q. Wu, R. E. Mclendon, et al., "Glioma Stem Cells Promote Radioresistance by Preferential Activation of the DNA Damage Response," *Nature* 444, no. 7120 (2006): 756–760, https://doi.org/10.1038/nature05236.

11. S. K. Singh, I. D. Clarke, M. Terasaki, et al., "Identification of a Cancer Stem Cell in Human Brain Tumors," *Cancer Research* 63 (2003): 5821–5828.

12. S. K. Singh, C. Hawkins, I. D. Clarke, et al., "Identification of Human Brain Tumour Initiating Cells," *Nature* 432, no. 7015 (2004): 396–401, https://doi.org/10.1038/nature03128.

13. X. Yuan, J. Curtin, Y. Xiong, et al., "Isolation of Cancer Stem Cells From Adult Glioblastoma Multiforme," *Oncogene* 23, no. 58 (2004): 9392–9400, https://doi.org/10.1038/sj.onc.1208311.

14. J. Yin, S. S. Kim, E. Choi, et al., "ARS2/MAGL Signaling in Glioblastoma Stem Cells Promotes Self-Renewal and M2-Like Polarization of Tumor-Associated Macrophages," *Nature Communications* 11, no. 1 (2020): 2978, https://doi.org/10.1038/s41467-020-16789-2.

15. W. Lin, R. Niu, S. M. Park, et al., "IGFBP5 is an ROR1 Ligand Promoting Glioblastoma Invasion via ROR1/HER2-CREB Signaling Axis," *Nature Communications* 14, no. 1 (2023): 1578, https://doi.org/10.1038/s41467-023-37306-1.

16. P. Stanley, "Golgi Glycosylation," *Cold Spring Harbor Perspectives in Biology* 3, no. 4 (2011): a005199–a005199, https://doi.org/10.1101/cshperspect.a005199.

17. K. T. Schjoldager, Y. Narimatsu, H. J. Joshi, et al., "Global View of Human Protein Glycosylation Pathways and Functions," *Nature Reviews Molecular Cell Biology* 21, no. 12 (2020): 729–749, https://doi.org/10.1038/s41580-020-00294-x.

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

18. S. S. Pinho and C. A. Reis, "Glycosylation in Cancer: Mechanisms and Clinical Implications," *Nature Reviews Cancer* 15, no. 9 (2015): 540–555, https://doi.org/10.1038/nrc3982.

19. J. C. M. D. F. Junior and A. J. A. Morgado-Díaz, "The Role of N-Glycans in Colorectal Cancer Progression: Potential Biomarkers and Therapeutic Applications," *Oncotarget* 7, no. 15 (2015): 19395–19413, https://doi.org/10.18632/oncotarget.6283.

20. H. Lemjabbar-Alaoui, A. McKinney, Y. W. Yang, et al., "Glycosylation Alterations in Lung and Brain Cancer," *Advances in Cancer Research* 126 (2015): 305–344.

21. S. R. Stowell, T. Ju, and R. D. Cummings, "Protein Glycosylation in Cancer," *Annual Review of Pathology* 10 (2015): 473–510, https://doi.org/10.1146/annurev-pathol-012414-040438.

22. E. Meezan, H. C. Wu, H. Paul, and A. P. W. R. Black, "Comparative Studies on the Carbohydrate-Containing Membrane Components of Normal and Virus-Transformed Mouse Fibroblasts. II. Separation of Glycoproteins and Glycopeptides by Sephadex Chromatography," *Biochemistry* 8, no. 6 (1969): 2518–2524, https://doi.org/10.1021/bi00834a039.

23. F. M. Tuccillo, A. De Laurentiis, C. Palmieri, et al., "Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43," *BioMed Research International* 2014 (2014): 1–13, https://doi.org/10.1155/2014/742831.

24. D. L. Meany and D. W. Chan, "Aberrant Glycosylation Associated With Enzymes as Cancer Biomarkers," *Clinical Proteomics* 8, no. 1 (2011): 7, https://doi.org/10.1186/1559-0275-8-7.

25. I. Hauselmann and L. Borsig, "Altered Tumor-Cell Glycosylation Promotes Metastasis," *Frontiers in Oncology* 4 (2014): 28, https://doi.org/10.3389/fonc.2014.00028.

26. D. H. Dube and C. R. Bertozzi, "Glycans in Cancer and Inflammation—Potential for Therapeutics and Diagnostics," *Nature Reviews Drug Discovery* 4, no. 6 (2005): 477–488, https://doi.org/10.1038/nrd1751.

27. J. Munkley and A. D. J. Elliott, "Hallmarks of Glycosylation in Cancer," *Oncotarget* 7, no. 23 (2016): 35478–35489, https://doi.org/10.18632/oncotarget.8155.

28. L. Veillon, C. Fakih, H. Abou-El-Hassan, et al., "Glycosylation Changes in Brain Cancer," *ACS Chemical Neuroscience* 9, no. 1 (2018): 51–72, https://doi.org/10.1021/acschemneuro.7b00271.

29. L. Oliveira-Ferrer, K. Legler, and K. Milde-Langosch, "Role of Protein Glycosylation in Cancer Metastasis," *Seminars in Cancer Biology* 44 (2017): 141–152, https://doi.org/10.1016/j.semcancer.2017.03.002.

30. A. Peixoto, M. Relvas-Santos, R. Azevedo, et al., "Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks," *Frontiers in Oncology* 9 (2019): 380, https://doi.org/10.3389/fonc.2019.00380.

31. K. Liu, L. Jiang, Y. Shi, et al., "Hypoxia-Induced GLT8D1 Promotes Glioma Stem Cell Maintenance by Inhibiting CD133 Degradation Through N-Linked Glycosylation," *Cell Death and Differentiation* 29, no. 9 (2022): 1834–1849, https://doi.org/10.1038/s41418-022-00969-2.

32. K. Fukuta, R. Abe, T. Yokomatsu, et al., "The Widespread Effect of β1,4-Galactosyltransferase on N-Glycan Processing," *Archives of Biochemistry and Biophysics* 392, no. 1 (2001): 79–86, https://doi.org/10.1006/abbi.2001.2421.

33. L. Cao, Y. Zhou, X. Li, et al., "Integrating Transcriptomics, Proteomics, Glycomics and Glycoproteomics to Characterize Paclitaxel Resistance in Breast Cancer Cells," *Journal of Proteomics* 243 (2021): 104266, https://doi.org/10.1016/j.jprot.2021.104266.

34. A. M. Abdel Rahman, M. Ryczko, M. Nakano, et al., "Golgi N-Glycan Branching N-Acetylglucosaminyltransferases I, V and VI Promote Nutrient Uptake and Metabolism," *Glycobiology* 25, no. 2 (2015): 225–240, https://doi.org/10.1093/glycob/cwu105.

35. R. Beheshti Zavareh, M. A. Sukhai, R. Hurren, et al., "Suppression of Cancer Progression by MGAT1 shRNA Knockdown," *PLoS ONE* 7, no. 9 (2012): e43721, https://doi.org/10.1371/journal.pone.0043721.

36. H. M. Cha, J. H. Lim, J. H. Yeon, et al., "Co-Overexpression of Mgat1 and Mgat4 in CHO Cells for Production of Highly Sialylated Albumin-Erythropoietin," *Enzyme and Microbial Technology* 103 (2017): 53–58, https://doi.org/10.1016/j.enzmictec.2017.04.010.

37. C. A. Vaiana, T. Kurcon, and L. K. Mahal, "MicroRNA-424 Predicts a Role for β-1,4 Branched Glycosylation in Cell Cycle Progression," *Journal of Biological Chemistry* 291, no. 3 (2016): 1529–1537, https://doi.org/10.1074/jbc.M115.672220.

38. A. S. Sultan, E. Miyoshi, Y. Ihara, et al., "Bisecting GlcNAc Structures Act as Negative Sorting Signals for Cell Surface Glycoproteins in Forskolin-Treated Rat Hepatoma Cells," *Journal of Biological Chemistry* 272, no. 5 (1997): 2866–2872, https://doi.org/10.1074/jbc.272.5.2866.

39. M. M. Fuster and J. D. Esko, "The Sweet and Sour of Cancer: Glycans as Novel Therapeutic Targets," *Nature Reviews Cancer* 5, no. 7 (2005): 526–542, https://doi.org/10.1038/nrc1649.

40. E. Rodriguez, S. T. T. Schetters, and Y. Van Kooyk, "The Tumour Glyco-Code as a Novel Immune Checkpoint for Immunotherapy," *Nature Reviews Immunology* 18, no. 3 (2018): 204–211, https://doi.org/10.1038/nri.2018.3.

41. H. Nie, X. Liu, Y. Zhang, et al., "Specific N-Glycans of Hepatocellular Carcinoma Cell Surface and the Abnormal Increase of Core-α-1, 6-Fucosylated Triantennary Glycan via N-Acetylglucosaminyltransferases-IVa Regulation," *Scientific Reports* 5 (2015): 16007, https://doi.org/10.1038/srep16007.

42. Y. Guo, S. Li, J. Qu, et al., "Let-7c Inhibits Metastatic Ability of Mouse Hepatocarcinoma Cells via Targeting Mannoside Acetylglucosaminyltransferase 4 Isoenzyme A," *International Journal of Biochemistry & Cell Biology* 53 (2014): 1–8, https://doi.org/10.1016/j.biocel.2014.04.012.

43. S. Takamatsu, A. Antonopoulos, K. Ohtsubo, et al., "Physiological and Glycomic Characterization of N-Acetylglucosaminyltransferase-IVa and -IVb Double Deficient Mice," *Glycobiology* 20, no. 4 (2010): 485–497, https://doi.org/10.1093/glycob/cwp200.

44. N. Osada, M. Nagae, M. Nakano, et al., "Examination of Differential Glycoprotein Preferences of N-Acetylglucosaminyltransferase-IV Isozymes a and b," *Journal of Biological Chemistry* 298, no. 9 (2022): 102400, https://doi.org/10.1016/j.jbc.2022.102400.

45. S. Oguri, A. Yoshida, M. T. Minowa, et al., "Kinetic Properties and Substrate Specificities of Two Recombinant Human N-Acetylglucosaminyltransferase-IV Isozymes," *Glycoconjugate Journal* 23, no. 7–8 (2006): 473–480, https://doi.org/10.1007/s10719-006-6216-3.

46. K. Niimi, E. Yamamoto, S. Fujiwara, et al., "High Expression of N-Acetylglucosaminyltransferase IVa Promotes Invasion of Choriocarcinoma," *British Journal of Cancer* 107, no. 12 (2012): 1969–1977, https://doi.org/10.1038/bjc.2012.496.

47. T. Shinji, O. Suguru, M. Mari Toba, et al., "Unusually High Expression of N-Acetylglucosaminyltransferase-IVa in Human Choriocarcinoma Cell Lines: A Possible Enzymatic Basis of the Formation of Abnormal Biantennary Sugar Chain," *Cancer Research* 59 (1999): 3949–3953.

48. K. Nishino, E. Yamamoto, K. Niimi, et al., "N-Acetylglucosaminyltransferase IVa Promotes Invasion of Choriocarcinoma," *Oncology Reports* 38, no. 1 (2017): 440–448, https://doi.org/10.3892/or.2017.5661.

49. J. Fan, S. Wang, S. Yu, et al., "N-Acetylglucosaminyltransferase IVa Regulates Metastatic Potential of Mouse Hepatocarcinoma Cells Through Glycosylation of CD147," *Glycoconjugate Journal* 29, no. 5–6 (2012): 323–334, https://doi.org/10.1007/s10719-012-9414-1.

50. T. Kudo, H. Nakagawa, M. Takahashi, et al., "N-Glycan Alterations are Associated With Drug Resistance in Human Hepatocellular Carcinoma," *Molecular Cancer* 6 (2007): 32, https://doi.org/10.1186/1476-4598-6-32.

51. A. D'arrigo, C. Belluco, A. Ambrosi, et al., "Metastatic Transcriptional Pattern Revealed by Gene Expression Profiling in Primary Colorectal Carcinoma," *International Journal of Cancer* 115, no. 2 (2005): 256–262, https://doi.org/10.1002/ijc.20883.

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

52. Y. Ide, E. Miyoshi, T. Nakagawa, et al., "Aberrant Expression of N-Acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in Pancreatic Cancer," *Biochemical and Biophysical Research Communications* 341, no. 2 (2006): 478–482, https://doi.org/10.1016/j.bbrc.2005.12.208.

53. D. C. Mcfarland, D. R. Jutagir, B. Rosenfeld, et al., "Depression and Inflammation Among Epidermal Growth Factor Receptor (EGFR) Mutant Nonsmall Cell Lung Cancer Patients," *Psycho-Oncology* 28, no. 7 (2019): 1461–1469.

54. Z. An, O. Aksoy, T. Zheng, et al., "Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma: Signaling Pathways and Targeted Therapies," *Oncogene* 37, no. 12 (2018): 1561–1575, https://doi.org/10.1038/s41388-017-0045-7.

55. E. Eskilsson, G. V. Rosland, G. Solecki, et al., "EGFR Heterogeneity and Implications for Therapeutic Intervention in Glioblastoma," *Neuro-Oncology* 20, no. 6 (2018): 743–752, https://doi.org/10.1093/neuonc/nox191.

56. Y. Zou, X. Sun, Q. Yang, et al., "Blood-Brain Barrier-Penetrating Single CRISPR-Cas9 Nanocapsules for Effective and Safe Glioblastoma Gene Therapy," *Science Advances* 8, no. 16 (2022): eabm8011, https://doi.org/10.1126/sciadv.abm8011.

57. G. Chen, A. A. Abdeen, Y. Wang, et al., "A Biodegradable Nanocapsule Delivers a Cas9 Ribonucleoprotein Complex for In Vivo Genome Editing," *Nature Nanotechnology* 14, no. 10 (2019): 974–980, https://doi.org/10.1038/s41565-019-0539-2.

58. Y. Jiang, J. Zhang, F. Meng, et al., "Apolipoprotein E Peptide-Directed Chimeric Polymersomes Mediate an Ultrahigh-Efficiency Targeted Protein Therapy for Glioblastoma," *ACS Nano* 12, no. 11 (2018): 11070–11079, https://doi.org/10.1021/acsnano.8b05265.

59. Z. Mirza, H. J. Schulten, H. M. Farsi, et al., "Molecular Interaction of a Kinase Inhibitor Midostaurin With Anticancer Drug Targets, S100A8 and EGFR: Transcriptional Profiling and Molecular Docking Study for Kidney Cancer Therapeutics," *PLoS ONE* 10, no. 3 (2015): e0119765, https://doi.org/10.1371/journal.pone.0119765.

60. G. Da Cunha Santos, F. A. Shepherd, and M. S. Tsao, "EGFR Mutations and Lung Cancer," *Annual Review of Pathology* 6 (2011): 49–69, https://doi.org/10.1146/annurev-pathol-011110-130206.

61. Y. Xiong, L. Yuan, S. Chen, et al., "WFDC2 Suppresses Prostate Cancer Metastasis by Modulating EGFR Signaling Inactivation," *Cell Death & Disease* 11, no. 7 (2020): 537, https://doi.org/10.1038/s41419-020-02752-y.

62. Y. N. Wang, H. H. Lee, C. K. Chou, et al., "Angiogenin/Ribonuclease 5 is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer," *Cancer Cell* 33, no. 4 (2018): 752–769.e8, https://doi.org/10.1016/j.ccell.2018.02.012.

63. F. Sobande, L. Dušek, A. Matějková, et al., "EGFR in Triple Negative Breast Carcinoma: Significance of Protein Expression and High Gene Copy Number," *Ceskoslovenska Patologie* 51, no. 2 (2015): 80–86.

64. H. Li, A. Al-Japairai, Y. Tao, and Z. Xiang, "RPN2 Promotes Colorectal Cancer Cell Proliferation Through Modulating the Glycosylation Status of EGFR," *Oncotarget* 8 (2017): 72651.

65. H. Hou, H. Sun, P. Lu, et al., "Tunicamycin Potentiates Cisplatin Anticancer Efficacy Through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma," *Molecular Cancer Therapeutics* 12, no. 12 (2013): 2874–2884, https://doi.org/10.1158/1535-7163.MCT-13-0201.

66. E. S. Taylor, L. Pol-Fachin, R. D. Lins, et al., "Conformational Stability of the Epidermal Growth Factor (EGF) Receptor as Influenced by Glycosylation, Dimerization and EGF Hormone Binding," *Proteins* 85, no. 4 (2017): 561–570, https://doi.org/10.1002/prot.25220.

67. J. Guo, M. Gu, Y. Chen, et al., "Nucleic Acid Delivery by Lipid Nanoparticles for Organ Targeting," *Chinese Chemical Letters* 36 (2025): 110849, https://doi.org/10.1016/j.cclet.2025.110849.

68. S. Wang, K. Cheng, K. Chen, et al., "Nanoparticle-Based Medicines in Clinical Cancer Therapy," *Nano Today* 45 (2022): 101512, https://doi.org/10.1016/j.nantod.2022.101512.

69. N. Oka, A. Soeda, A. Inagaki, et al., "VEGF Promotes Tumorigenesis and Angiogenesis of Human Glioblastoma Stem Cells," *Biochemical and Biophysical Research Communications* 360, no. 3 (2007): 553–559, https://doi.org/10.1016/j.bbrc.2007.06.094.

70. K. M. Joo, J. Kim, J. Jin, et al., "Patient-Specific Orthotopic Glioblastoma Xenograft Models Recapitulate the Histopathology and Biology of Human Glioblastomas In Situ," *Cell Reports* 3, no. 1 (2013): 260–273, https://doi.org/10.1016/j.celrep.2012.12.013.

71. S. Zhou, W. Lin, X. Jin, et al., "CD97 Maintains Tumorigenicity of Glioblastoma Stem Cells via mTORC2 Signaling and is Targeted by CAR Th9 Cells," *Cell Reports Medicine* 5, no. 12 (2024): 101844, https://doi.org/10.1016/j.xcrm.2024.101844.

72. E. Kim, M. Kim, D. H. Woo, et al., "Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-Like Cells," *Cancer Cell* 23, no. 6 (2013): 839–852, https://doi.org/10.1016/j.ccr.2013.04.008.

73. P. Mao, K. Joshi, J. Li, et al., "Mesenchymal Glioma Stem Cells are Maintained by Activated Glycolytic Metabolism Involving Aldehyde Dehydrogenase 1A3," *PNAS* 110, no. 21 (2013): 8644–8649, https://doi.org/10.1073/pnas.1221478110.

74. J. Yin, Y. T. Oh, J.-Y. Kim, et al., "Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling," *Cancer Research* 77, no. 18 (2017): 4973–4984, https://doi.org/10.1158/0008-5472.CAN-17-0388.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.

Supporting Information file 1: exp270115-sup-0001-SuppMat.pdf

Supporting Information file 2: exp270115-sup-0002-Table.pdf

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250153 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License